Lilly marks a first with Humalog U-200 KwikPen
INDIANAPOLIS — Eli Lilly and Co. has been cleared by the Food and Drug Administration to market the Humalog 200 units/ml KwikPen, which the company called the first concentrated mealtime insulin analog approved in the United States. Lilly said Wednesday that the Humalog 200 units/ml KwikPen (insulin lispro 200 units/ml, U-200) is a prefilled pen
